pomalidomide + pegylated liposomal doxorubicin + dexamethasone

This is a **three-drug combination therapy** consisting of **pomalidomide**, **pegylated liposomal doxorubicin**, and **dexamethasone**, researched for use in patients with **relapsed or refractory multiple myeloma** who have received prior therapies including lenalidomide and bortezomib. - **Pomalidomide** is an immunomodulatory agent that enhances immune cell function and has antineoplastic activity, mainly through binding cereblon, leading to degradation of specific substrates and modulation of cytokine production. - **Pegylated liposomal doxorubicin** is a cytotoxic anthracycline antibiotic, encapsulated in liposomes for improved tumor targeting and reduced toxicity, whose primary mechanism is inhibition of topoisomerase II, resulting in DNA damage and apoptosis. - **Dexamethasone** is a synthetic glucocorticoid that exerts lympholytic, anti-inflammatory, and immunosuppressive effects, enhancing antitumor efficacy. The combination aims to potentiate antimyeloma activity by targeting both the tumor cells directly and the microenvironment, and to overcome drug resistance seen in advanced myeloma. This regimen is investigated primarily in advanced/refractory settings, including patients who have exhausted standard therapies[1].